Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Application of NY-ESO-1-specific TCR Affinity Enhancing Specific T Cell Therapy (TAEST16001) in Solid Tumors Except Non Small Cell Lung Cancer,Including Liver Cancer,Gastric Cancer,Esophageal Cancer and so on.

NCT03159585 is registered in ClinicalTrials.gov with Zhujiang Hospital as lead sponsor.

NCT NCT03159585
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03159585 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Application of NY-ESO-1-specific TCR Affinity Enhancing Specific T Cell Therapy (TAEST16001) in Solid Tumors Except Non Small Cell Lung Cancer,Including Liver Cancer,Gastric Cancer,Esophageal Cancer and so on.
Lead sponsor
Zhujiang Hospital
Phase
Phase 1
Overall status
Completed
Start date
April 14, 2017
Completion date
June 4, 2019
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder carcinoma stage iv, bone and soft tissue tumors, breast cancer stage iv, esophageal cancer, stage iv, gastric cancer stage iv, liver cancer stage iv, ovarian cancer stage iv, prostate carcinoma stage iv, solid tumor, thyroid cancer stage iv